Skip to main content
  • Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

    • More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options
    • The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)
    • The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD

    ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details